Ionis Pharmaceuticals (IONS) Appoints Michael Yang to its Board

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10.

Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and Board member of ViaCyte, which was acquired by Vertex in 2022. Prior to ViaCyte, Mr. Yang was Executive Vice President and Chief Commercial Officer at Acadia Pharmaceuticals from 2017 to 2021. During his tenure, Acadia transformed the standard of care for patients with Parkinson's disease psychosis. Prior to Acadia, Mr. Yang was President of Janssen Biotech Inc., where he was responsible for building Janssen's U.S. immunology business, generating more than $8 billion in annual revenues.

"We are thrilled for Michael to join the Board as he adds deep biopharmaceutical leadership experience, particularly important as Ionis is poised to enter its next phase of growth," said Joseph Loscalzo, M.D., Ph.D., chairman of the Ionis Board of Directors. "Michael's commercial experience launching innovative medicines for patients in need will be highly complementary to the strong science and business expertise on the Board. We welcome his guidance and insights."

"I have known Michael for many years and have always appreciated his wide-ranging experience in both rare and common diseases as well as the strong patient focus he brings to our industry," said Brett P. Monia, Ph.D., Ionis' chief executive officer. "We are thrilled to have him as part of the Board and the Ionis team looks forward to working with him."

You May Also Be Interested In

• Targa Resources adds ex-ConocoPhillips executive to its board
• Increasing unusual option volume: BCE EQPT MDY DOMO CC IONS ARKG FRMM TOI DINO
• Docebo launches $70M share buyback at $20.40 per share